BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30730936)

  • 1. Comparison of therapeutic evaluation criteria in FDG-PET/CT in patients with diffuse large-cell B-cell lymphoma: Prognostic impact of tumor/liver ratio.
    Toledano MN; Vera P; Tilly H; Jardin F; Becker S
    PLoS One; 2019; 14(2):e0211649. PubMed ID: 30730936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUV
    Li YH; Zhao YM; Jiang YL; Tang S; Chen MT; Xiao ZZ; Fan W; Hu YY; Zhang X
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1311-1321. PubMed ID: 34651231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B-cell lymphoma.
    Li X; Sun X; Li J; Liu Z; Mi M; Zhu F; Wu G; Lan X; Zhang L
    Cancer Med; 2019 Sep; 8(11):5012-5022. PubMed ID: 31293092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic analysis of interim
    Yuan L; Kreissl MC; Su L; Wu Z; Hacker M; Liu J; Zhang X; Bo Y; Zhang H; Li X; Li S
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):478-488. PubMed ID: 30382301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of Dmax and %ΔSUVmax of
    Dang J; Peng X; Wu P; Yao Y; Tan X; Ye Z; Jiang X; Jiang X; Liu Y; Chen S; Cheng Z
    BMC Med Imaging; 2023 Oct; 23(1):173. PubMed ID: 37907837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Values of Different Evaluation Criteria of Interim
    Zhu LT; Cen XN; Ou JP; Qiu ZX; Wang LH; Liu W; Wang WS; Dong YJ; Liang ZY; Wang MJ; Xu WL; Sun YH; Wang Q; Yin Y; Ren HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):431-437. PubMed ID: 28446288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Pre-Autologous Stem Cell Transplantation PET/CT in Diffuse Large B-Cell Lymphoma: The Deauville Score Is Prognostically Superior to ΔSUVmax.
    Zhang XY; Song L; Wang PJ; Wang L; Li Y; Wang YY; Shi CL
    Acta Haematol; 2020; 143(2):124-130. PubMed ID: 31382264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax.
    Itti E; Meignan M; Berriolo-Riedinger A; Biggi A; Cashen AF; Véra P; Tilly H; Siegel BA; Gallamini A; Casasnovas RO; Haioun C
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1312-20. PubMed ID: 23649463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the SUV
    Zhang Y; Fan Y; Ying Z; Song Y; Zhu J; Yang Z; Wang X
    Leuk Lymphoma; 2018 Mar; 59(3):660-669. PubMed ID: 28771052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the ΔSUV
    Itti E; Blanc-Durand P; Berriolo-Riedinger A; Kanoun S; Kraeber-Bodéré F; Meignan M; Gat E; Gouill SL; Casasnovas RO; Bodet-Milin C
    J Nucl Med; 2023 Nov; 64(11):1706-1711. PubMed ID: 37734837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
    Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
    Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of outcome in pediatric Hodgkin lymphoma based on interpretation of
    Isik EG; Kuyumcu S; Kebudi R; Sanli Y; Karakas Z; Cakir FB; Unal SN
    Ann Nucl Med; 2017 Nov; 31(9):660-668. PubMed ID: 28741053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognostic Value of Interim PET/CT in 227 Patients of DLBCL].
    Wang RM; Li F; Liu CB; Guan ZW; Fu LP; Xu BX; Zhu HY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2019 Feb; 27(1):74-79. PubMed ID: 30738450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interobserver Agreement of Interim and End-of-Treatment
    Burggraaff CN; Cornelisse AC; Hoekstra OS; Lugtenburg PJ; De Keizer B; Arens AIJ; Celik F; Huijbregts JE; De Vet HCW; Zijlstra JM;
    J Nucl Med; 2018 Dec; 59(12):1831-1836. PubMed ID: 29728515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicting primary treatment failure using interim FDG-PET scanning in diffuse large B-cell lymphoma.
    Wight J; Wai SH; Shen E; Lee ST; Berlangieri S; Fancourt T; Hawkes E; Hannah A; Leung T; Chong G
    Eur J Haematol; 2021 Oct; 107(4):475-483. PubMed ID: 34240453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG-PET/CT at the end of immuno-chemotherapy in follicular lymphoma: the prognostic role of the ratio between target lesion and liver SUV
    Annunziata S; Cuccaro A; Tisi MC; Hohaus S; Rufini V
    Ann Nucl Med; 2018 Jun; 32(5):372-377. PubMed ID: 29464479
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Burggraaff CN; Eertink JJ; Lugtenburg PJ; Hoekstra OS; Arens AIJ; de Keizer B; Heymans MW; van der Holt B; Wiegers SE; Pieplenbosch S; Boellaard R; de Vet HCW; Zijlstra JM;
    J Nucl Med; 2022 Jul; 63(7):1001-1007. PubMed ID: 34675112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 19. Predicting diffuse large B-cell lymphoma outcomes with lesion-to-liver maximum standardized uptake value for interim-treatment and end-of-treatment positron emission tomography-computed tomography.
    Wang L; Zhang S; Xin J
    Quant Imaging Med Surg; 2023 Oct; 13(10):6789-6800. PubMed ID: 37869355
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUV
    Rekowski J; Hüttmann A; Schmitz C; Müller SP; Kurch L; Kotzerke J; Franzius C; Weckesser M; Bengel FM; Freesmeyer M; Hertel A; Krohn T; Holzinger J; Brink I; Haberkorn U; Nyuyki F; van Assema DME; Geworski L; Hasenclever D; Jöckel KH; Dührsen U
    J Nucl Med; 2021 Jan; 62(1):37-42. PubMed ID: 32385164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.